Cargando…

Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects

In an aging society, Alzheimer’s disease (AD) exerts an increasingly serious health and economic burden. Current treatments provide inadequate symptomatic relief as several distinct pathological processes are thought to underlie the decline of cognitive and neural function seen in AD. This suggests...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scuderi, Caterina, Bronzuoli, Maria Rosanna, Facchinetti, Roberta, Pace, Lorenzo, Ferraro, Luca, Broad, Kevin Donald, Serviddio, Gaetano, Bellanti, Francesco, Palombelli, Gianmauro, Carpinelli, Giulia, Canese, Rossella, Gaetani, Silvana, Steardo, Luca, Cassano, Tommaso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802581/ https://www.ncbi.nlm.nih.gov/pubmed/29382825 http://dx.doi.org/10.1038/s41398-017-0076-4

Ejemplares similares

Effects of Ultramicronized Palmitoylethanolamide on Mitochondrial Bioenergetics, Cerebral Metabolism, and Glutamatergic Transmission: An Integrated Approach in a Triple Transgenic Mouse Model of Alzheimer's Disease
por: Bellanti, Francesco, et al.
Publicado: (2022)

Looking for a Treatment for the Early Stage of Alzheimer’s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin
por: Facchinetti, Roberta, et al.
Publicado: (2020)

Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2018)

Co-Ultramicronized Palmitoylethanolamide/Luteolin Restores Oligodendrocyte Homeostasis via Peroxisome Proliferator-Activated Receptor-α in an In Vitro Model of Alzheimer’s Disease
por: Facchinetti, Roberta, et al.
Publicado: (2022)

Palmitoylethanolamide and White Matter Lesions: Evidence for Therapeutic Implications
por: Valenza, Marta, et al.
Publicado: (2022)

Astrocyte Function Is Affected by Aging and Not Alzheimer’s Disease: A Preliminary Investigation in Hippocampi of 3xTg-AD Mice
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2019)

Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease
por: Scuderi, C, et al.
Publicado: (2014)

Targeting neuroinflammation in Alzheimer’s disease
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2016)

Palmitoylethanolamide exerts neuroprotective effects in mixed neuroglial cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-α
por: Scuderi, Caterina, et al.
Publicado: (2012)

Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes
por: Steardo, Luca, et al.
Publicado: (2015)

Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide
por: Scuderi, Caterina, et al.
Publicado: (2011)

Neuroglia in the autistic brain: evidence from a preclinical model
por: Bronzuoli, Maria Rosanna, et al.
Publicado: (2018)

Ultramicronized Palmitoylethanolamide Inhibits NLRP3 Inflammasome Expression and Pro-Inflammatory Response Activated by SARS-CoV-2 Spike Protein in Cultured Murine Alveolar Macrophages
por: Del Re, Alessandro, et al.
Publicado: (2021)

Add-on administration of ultramicronized palmitoylethanolamide in the treatment of new-onset burning mouth syndrome
por: Chirchiglia, Domenico, et al.
Publicado: (2019)

Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation
por: Roncati, Luca, et al.
Publicado: (2021)

Astrocytes and the Psychiatric Sequelae of COVID-19: What We Learned from the Pandemic
por: Steardo, Luca, et al.
Publicado: (2022)

Altered Waste Disposal System in Aging and Alzheimer’s Disease: Focus on Astrocytic Aquaporin-4
por: Valenza, Marta, et al.
Publicado: (2020)

Ultramicronized Palmitoylethanolamide in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation
por: D’Amico, Ramona, et al.
Publicado: (2021)

Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man
por: Caltagirone, Carlo, et al.
Publicado: (2015)

Alternative Targets to Fight Alzheimer’s Disease: Focus on Astrocytes
por: Valenza, Marta, et al.
Publicado: (2021)

Systemic Inflammation and Astrocyte Reactivity in the Neuropsychiatric Sequelae of COVID-19: Focus on Autism Spectrum Disorders
por: Valenza, Marta, et al.
Publicado: (2021)

Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain
por: Cocito, Dario, et al.
Publicado: (2014)

Sirtuin modulators control reactive gliosis in an in vitro model of Alzheimer’s disease
por: Scuderi, Caterina, et al.
Publicado: (2014)

Editorial: Dysmetabolism, Obesity, and Inflammation: Three Prominent Actors in the Drama of Major Neuropsychiatric Disorders
por: Cassano, Tommaso, et al.
Publicado: (2016)

Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells
por: Barbierato, Massimo, et al.
Publicado: (2015)

Comment on “Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain”
por: Kriek, R.
Publicado: (2014)

A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury
por: Paterniti, Irene, et al.
Publicado: (2013)

Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect
por: Petrosino, Stefania, et al.
Publicado: (2018)

Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain
por: Impellizzeri, Daniela, et al.
Publicado: (2014)

Erratum to: A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury
por: Paterniti, Irene, et al.
Publicado: (2016)

Erratum to: Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain
por: Impellizzeri, Daniela, et al.
Publicado: (2016)

Co-Ultramicronized Palmitoylethanolamide/Luteolin Promotes Neuronal Regeneration after Spinal Cord Injury
por: Crupi, Rosalia, et al.
Publicado: (2016)

Combination of Rehabilitative Therapy with Ultramicronized Palmitoylethanolamide for Chronic Low Back Pain: An Observational Study
por: Scaturro, Dalila, et al.
Publicado: (2019)

Psychiatric face of COVID-19
por: Steardo, Luca, et al.
Publicado: (2020)

Co-ultramicronized palmitoylethanolamide/luteolin normalizes GABA(B)-ergic activity and cortical plasticity in long COVID-19 syndrome
por: Versace, Viviana, et al.
Publicado: (2023)

Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients
por: Noce, Annalisa, et al.
Publicado: (2021)

Ultramicronized Palmitoylethanolamide and Paracetamol, a New Association to Relieve Hyperalgesia and Pain in a Sciatic Nerve Injury Model in Rat
por: Peritore, Alessio Filippo, et al.
Publicado: (2020)

Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study
por: Stochino Loi, Emanuela, et al.
Publicado: (2019)

S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells
por: Esposito, Giuseppe, et al.
Publicado: (2008)

Oral Adelmidrol Administration Up-Regulates Palmitoylethanolamide Production in Mice Colon and Duodenum through a PPAR-γ Independent Action
por: Del Re, Alessandro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dbadlldp7igamgi6rs6uo064p0